ABUS
Arbutus Biopharma Corp
Key Financials
Net Income
$-33501000
↑ 52.1%
Revenue
$14.1M
↑ 128.2%
Operating Income
$-38160000
↑ 50.0%
Total Assets
$94.6M
↓ 28.2%
EPS (Diluted)
$-0.17
↑ 55.3%
Total Liabilities
$18.0M
↓ 47.5%
Cash & Equivalents
$18.0M
↓ 50.4%
Shareholders' Equity
$76.6M
↓ 21.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/10/2026 | View on SEC |
| 4 | 6/10/2026 | View on SEC |
| S-8 | 6/5/2026 | View on SEC |
| 8-K | 5/27/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| SCHEDULE 13D/A | 4/28/2026 | View on SEC |
| 8-K | 4/15/2026 | View on SEC |
| DEFA14A | 4/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ABUS |
| Company Name | Arbutus Biopharma Corp |
| CIK | 1447028 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | A1 |
| Phone | 604-419-3200 |